Want to see MEDP full AI Analyst Report?
MEDP Stock Chart & Stats
$520.60
$7.21(2.08%)
At close: 4:00 PM EST
$520.60
$7.21(2.08%)
Day’s Range― - ―
52-Week Range$306.70 - $628.92
Previous CloseN/A
Volume64.09K
Average Volume (3M)297.63K
Market Cap
$15.36B
Enterprise Value$13.40K
Total Cash (Recent Filing)$652.68M
Total Debt (Recent Filing)$122.26M
Price to Earnings (P/E)33.1
Beta1.08
Next Earnings
Jul 22, 2026EPS Estimate
3.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.24
Shares Outstanding28,559,689
10 Day Avg. Volume261,938
30 Day Avg. Volume297,627
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$472.89Price Target Upside-9.16% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)16.99
Revenue Forecast (FY)$2.78B
Bulls Say, Bears Say
Bulls Say
Very Strong Free Cash Flow GenerationMedpace converts nearly all reported earnings into free cash flow (TTM FCF ~$745M and ~0.99x conversion). This durable cash generation supports reinvestment, working-capital cushions, debt flexibility and optional capital returns during cycles of booking volatility.
Healthy And Expanding Operating MarginsSustained mid-to-high teens net margins and ~21% EBIT reflect scalable service economics in complex, high-value CRO work. Strong margins provide buffer against price pressure and fund investment in therapeutic expertise that underpins long-term competitive position.
Large, Multi-year Backlog With Near-term ConvertibilityA sizable multi-year backlog gives visible revenue runway and multi-quarter cash flow predictability. With a large portion slated to convert within 12 months, the business retains durable revenue coverage that smooths cycles and supports capacity planning and margin retention.
Bears Say
Elevated Cancellations And Weak Book-to-billRising cancellations and sub-1.0 net book-to-bill directly reduce backlog growth and future revenue visibility. If cancellations persist, they erode long-term contract conversion, force reallocation of resources, and impair the predictability that underpins CRO operating leverage.
Multi-quarter Decline In Beyond-12-month Backlog CoverageA sustained drop in >12-month backlog coverage weakens longer-term revenue visibility and increases reliance on near-term awards. This structural weakening raises execution risk, makes planning for capacity and hiring harder, and can compress future growth if pipeline recovery lags.
Customer Concentration RiskA material share of revenue from a small set of customers concentrates demand risk: any loss, reprioritization, or scope reduction at top clients can meaningfully impact revenue and utilization. This structural concentration raises sensitivity to individual sponsor decisions.
Medpace Holdings News
![Medpace Backs Phase 2 Cancer Imaging Trial With [68Ga]BED003](https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2170812299-150x150.jpg)
MEDP FAQ
What was Medpace Holdings Inc’s price range in the past 12 months?
Medpace Holdings Inc lowest stock price was $306.70 and its highest was $628.91 in the past 12 months.
What is Medpace Holdings Inc’s market cap?
Medpace Holdings Inc’s market cap is $15.36B.
When is Medpace Holdings Inc’s upcoming earnings report date?
Medpace Holdings Inc’s upcoming earnings report date is Jul 22, 2026 which is in 3 days.
How were Medpace Holdings Inc’s earnings last quarter?
Medpace Holdings Inc released its earnings results on Apr 22, 2026. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.921 by $0.359.
Is Medpace Holdings Inc overvalued?
According to Wall Street analysts Medpace Holdings Inc’s price is currently Overvalued.
Does Medpace Holdings Inc pay dividends?
Medpace Holdings Inc does not currently pay dividends.
What is Medpace Holdings Inc’s EPS estimate?
Medpace Holdings Inc’s EPS estimate is 3.98.
How many shares outstanding does Medpace Holdings Inc have?
Medpace Holdings Inc has 28,559,689 shares outstanding.
What happened to Medpace Holdings Inc’s price movement after its last earnings report?
Medpace Holdings Inc reported an EPS of $4.28 in its last earnings report, beating expectations of $3.921. Following the earnings report the stock price went down -22.625%.
Which hedge fund is a major shareholder of Medpace Holdings Inc?
Currently, no hedge funds are holding shares in MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$472.89 (-9.16% Downside)
$472.89 (-9.16% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 318.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.48%
12-Months-Change
Fundamentals
Return on Equity
120.89%
Trailing 12-Months
Asset Growth
12.24%
Trailing 12-Months
Company Description
Medpace Holdings Inc
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
MEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$472.89
▼(-9.16% Downside)
Technical Analysis
Ownership Overview
19.42% Insiders
21.34% Mutual Funds
2.90% Other Institutional Investors
34.18% Public Companies and
Individual Investors